´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.
Home > ÀüÁ¦Ç°º¸±â > Stem Cell > Overview > Áúº´ ¸ðµ¨ °³¹ßÀ» À§ÇÑ Solution

Áúº´ ¸ðµ¨ °³¹ßÀ» À§ÇÑ Solution

-

Human iPSC¸¦ »ç¿ëÇÑ Áúº´ ¸ðµ¨ Á¦ÀÛ°ú º´Å Çؼ® ¿¬±¸¸¦ À§ÇÑ
Cellartis¢ç iPS Cell to Hepatocyte Differentiation SystemÀÇ Àû¿ë»ç·Ê¸¦ È®ÀÎÇϼ¼¿ä.

  • ȯÀÚ À¯·¡ iPSC ¶Ç´Â À¯ÀüÀÚ ÆíÁýµÈ iPSC·ÎºÎÅÍ ÃÖÀûÈ­ °úÁ¤ ¾øÀÌ °£¼¼Æ÷·Î °í¼øµµ ºÐÈ­ (90% ÀÌ»ó)
  • CellartisÀÇ µ¶ÀÚÀûÀÎ ±â¼ú·Î iPSC Ãʺ¸ÀÚµµ ³ôÀº ºÐÈ­ È¿À²°ú ¾ÈÁ¤ÀûÀÎ ½ÇÇè °á°ú µµÃâ
  • ºÐÈ­ À¯µµ¿¡ ÇÊ¿äÇÑ ¹èÁö¸¦ ¸ðµÎ Æ÷ÇÔÇÑ All-in-One kit


1. ¼±Ãµ¼º °£ ¼¶À¯Áõ (Congential hepathic fibrosis) ¸ðµ¨ °³¹ß°ú º´Å ¿¬±¸
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU)
PhD. Sei Kakinuma
Cellartis¢ç iPS Cell to Hepatocyte Differentiation System (Code Y30055)À» ÀÌ¿ëÇÑ ¼±Ãµ¼º °£ ¼¶À¯Áõ ¸ðµ¨ Á¦ÀÛ°ú º´Å ±Ô¸íÀÇ ¿¬±¸ ¼º°ú°¡ Journal of Hepatology¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù.


[³í¹®¸í]
Tsunoda, Tomoyuki, et al. "Loss of fibrocystin promotes interleukin-8-dependent proliferation and CTGF production of biliary epithelium." Journal of hepatology 71.1 (2019): 143-152.



¼±Ãµ¼º °£¼¶À¯ÁõÀº žƱ⿡ ½ÃÀ۵Ǵ ´ã°ü Çü¼ºÀÇ ÀÌ»ó°ú °£¼¶À¯È­¸¦ ÀÏÀ¸Å°´Â À¯Àü¼º °£ÁúȯÀÌ´Ù. ¼Ò¾Æ±â¿¡ °£À̽ÄÀ» ÇÊ¿ä·Î ÇÒ ¼ö ÀÖ´Â ³­Ä¡¼º ÁúȯÀ¸·Î, ½Å±Ô Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ Áúº´¸ðµ¨ È®¸³ÀÌ ÇÊ¿äÇÑ »óÅÂÀÌ´Ù. Áö±Ý±îÁö´Â ÇØ´ç ÁúȯÀÇ ¸¶¿ì½º ¸ðµ¨À» ÀÌ¿ëÇÑ ¿¬±¸°¡ ÀÌ·ç¾îÁ³Áö¸¸, ¸¶¿ì½º ¸ðµ¨°ú ½ÇÁ¦ ȯÀÚÀÇ º´Å¿¡´Â °ÝÂ÷°¡ Å« °ÍÀÌ ÇÑ°è¿´´Ù. ¿¬±¸ÁøÀº Human iPSC¿¡¼­ º» ÁúȯÀ» ÀçÇö ¹× Çؼ®ÇÒ ¼ö ÀÖ´Â Áúº´ ¸ðµ¨À» Á¦ÀÛÇÏ¿©, ´ã°ü ¼¼Æ÷°¡ »ý¼ºÇÏ´Â IL-8ÀÌ º» Áúȯ¿¡¼­ º¼ ¼ö ÀÖ´Â ´ã°üÀÇ ÀÌ»ó°ú °£¼¶À¯È­ÀÇ ÁøÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÔÀ» ¹ß°ßÇÏ¿´´Ù. ¶ÇÇÑ, Human iPSC Áúº´ ¸ðµ¨¿¡¼­ ¾òÀº °á°ú´Â ¼±Ãµ¼º °£¼¶À¯ÁõÀ» °¡Áø ½ÇÁ¦ ȯÀÚ¿¡¼­µµ °üÂû ÇÒ ¼ö ÀÖ¾ú´Ù. µû¶ó¼­, º» ¿¬±¸¸¦ ÅëÇØ Human iPSC¸¦ ÀÌ¿ëÇÑ Áúº´ ¸ðµ¨À» °³¹ßÇÔÀ¸·Î½á, óÀ½À¸·Î ¼±Ãµ¼º °£¼¶À¯ÁõÀÇ º´Å¿¡ ´ëÇØ »ó¼¼ÇÑ ºÐÀÚ ¸ÞÄ¿´ÏÁòÀ» ¹àÇô³¾ ¼ö ÀÖ¾ú´Ù.



Human iPSC¸¦ DEF-CS¢â 500 Culture System¿¡¼­ À¯Áö ¹× ¹è¾ç ÈÄ, Cellartis¢ç iPS Cell to Hepatocyte Differentiation SystemÀ» »ç¿ëÇÏ¿© Hepatoblast stage±îÁö ºÐÈ­ À¯µµÇß´Ù. ºÐÈ­ À¯µµ 12ÀÏ°, À¯µµµÈ ¼¼Æ÷¸¦ ¹è¾çÇÏ¿© °£ Àü±¸ ¼¼Æ÷ (iPS-HPCs) colony¸¦ Çü¼º½ÃÄ×°í, ÀÌ ¼¼Æ÷¸¦ 3D ¹è¾çÀ¸·Î 10ÀÏ µ¿¾È Ãß°¡ ¹è¾çÇÏ¸é ´ã°ü »óÇÇ·Î ±¸¼ºµÈ ³¶(Cyst)ÇüÅ·ΠºÐÈ­µÇ¾ú´Ù. ¼±Ãµ¼º °£¼¶À¯Áõ ¸ðµ¨ÀÇ º¯ÀÌ ¼¼Æ÷´Â ÀÚÀ²ÀûÀ¸·Î IL-8À» ºÐºñÇÏ°í, ºÐºñµÈ IL-8¿¡ ÀÇÁ¸ÀûÀ¸·Î ´ã°ü ¼¼Æ÷°¡ Áõ½ÄÇÏ¿© CystÀÇ Å©±â¿Í ¼ö°¡ Áõ´ëÇÏ´Â °ÍÀ» È®ÀÎÇÏ¿´´Ù. ÀÌ·¯ÇÑ Çö»óÀº žƱâÀÇ ´ã°ü Çü¼º ÀÌ»óÀ¸·Î ÀÎÇÑ ÁúȯÀ» ¸ð¹æÇÏ°í ÀÖ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù.

(Tsunoda, et al.,Journal of Hepatology (2019) Àοë)
https://doi.org/10.1016/j.jhep.2019.02.024


Cellartis¢ç iPS Cell to Hepatocyte Differentiation SystemÀ» ¾î¶»°Ô »ç¿ëÇÏ°Ô µÇ¼Ì³ª¿ä?
- Á¦Ç°À» »ç¿ëÇÏ°íÀÖ´Â °øµ¿ ¿¬±¸ÀڷκÎÅÍ ¾ÈÁ¤ÀûÀ¸·Î ¹è¾çÀÌ °¡´ÉÇÏ´Ù°í µé¾ú½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸½Ç¿¡¼­
Feeder free ¹è¾çÀ¸·Î º¯°æÇÏ·Á´Â °èȹÀÌ ÀÖ¾ú±â ¶§¹®¿¡, º» Á¦Ç°À» »ç¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù.
   
½ÇÁ¦·Î »ç¿ëÇغ» ¼Ò°¨Àº ¾î¶»³ª¿ä?
- Feede-free ¹è¾çÀº ºñ±³Àû °£ÆíÇÔ°ú µ¿½Ã¿¡, human iPSC¸¦ ¾ÈÁ¤ÀûÀ¸·Î ¹è¾çÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù.ÀÌ ¿¬±¸¿¡¼­´Â
°£ Àü±¸ ¼¼Æ÷±îÁö ºÐÈ­½ÃŲ ÈÄ È®´ë ¹è¾çÇÏ¿© ´ã°ü ¼¼Æ÷·Î ºÐÈ­½ÃÅ°´Â ½ÇÇèÀ» ÁøÇàÇÏ¿´½À´Ï´Ù. ±âÁ¸ÀÇ °£¼¼Æ÷
°è¿­ÀÇ ºÐÈ­¿¡ »ç¿ëÇÑ ¹æ¹ýÀÇ °á°úº¸´Ù Àü¹ÝÀûÀÎ ºÐÈ­ À¯µµ °úÁ¤¿¡¼­ ¾ÈÁ¤ÀûÀÎ ÀçÇö¼ºÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.
   
¾ÆÁ÷ »ç¿ëÇغ¸Áö ¾ÊÀº ºÐµé²² ÇѸ¶µð ºÎŹ µå¸³´Ï´Ù.
- Human iPSCÀÇ À¯Áö ¹× ¹è¾ç »Ó¸¸¾Æ´Ï¶ó °£ ¼¼Æ÷ °è¿­ÀÇ ºÐÈ­ À¯µµ °ü·Ã ½ÇÇè±îÁö ¸ðµÎ, ÀçÇö¼ºÀÖ´Â ½ÇÇèÀÌ
°¡´ÉÇØ, human iPSCÀÇ »ç¿ë °æÇèÀÌ ÀûÀº ½ÇÇèÀÚ¶óµµ ¹è¾ç°ú ºÐÈ­ °úÁ¤À» ¾ÈÁ¤ÀûÀ¸·Î ÁøÇàÇÒ ¼ö ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù.



2. hiPSC¸¦ ÀÌ¿ëÇÑ ´Ù³¶¼º °£Áúȯ (polycystic liver disease)ÀÇ in vitro model Á¦ÀÛ
Department of Molecular Life sciences, Tokai University of Meticine
PhD. Akihide Kamiya
Tokai ÀÇ°ú´ëÇÐ ±âÃÊÀÇÇкΠºÐÀÚ»ý¹°°úÇаúÀÇ Tadahide Kotani ¹Ú»ç ¿¬±¸½Ç¿¡¼­ Cellartis¢ç iPS Cell To Hepatocyte Differentiation System (Code Y30055)À¸·Î °£ Áúº´ ¸ðµ¨À» Á¦ÀÛÇÏ¿´°í, ±× °á°ú°¡ Stem Cell Research¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù.


[Publication]
Kamiya, Akihide, et al. "An in vitro model of polycystic liver disease using genome-edited human inducible pluripotent stem cells." Stem cell research 32 (2018): 17-24



´Ù³¶¼º °£Áúȯ (Polycystic liver disease)Àº ´ãÁó°ü ¼¼Æ÷·ÎºÎÅÍ À¯·¡ÇÑ ³¶Á¾ÀÌ °£¿¡ ´ë·® ¹ß»ýÇÏ°í °Å´ëÈ­µÇ¸é¼­ ÁÖº¯ Àå±âµéÀ» ¾Ð¹ÚÇÏ´Â µî ¹®Á¦¸¦ À¯¹ßÇÏ´Â Èñ±ÍÁúȯÀÌ´Ù. ´ã°ü ¼¼Æ÷ÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇÑ ÀÌ»ó Áõ½ÄÀÌ ¿øÀÎÀ¸·Î ¿©°ÜÁö¸ç, Protein Kinase C substrate 80K-H (PRKCSH) µîÀÌ Áúº´ À¯¹ß À¯ÀüÀÚ·Î º¸°íµÇ°í ÀÖÁö¸¸, Àΰ£ ¼¼Æ÷¸¦ ÀÌ¿ëÇÑ ´Ù³¶¼º °£Áúȯ ½ÇÇè ¸ðµ¨ÀÌ ¾ø¾î Áúº´ Çؼ®¿¡ ¾î·Á¿òÀÌ ÀÖ¾ú´Ù.

º» ¿¬±¸¿¡¼­´Â ´ÙÀ½°ú °°ÀÌ ´Ù¹ß¼º °£Áúȯ ¸ðµ¨À» Á¦ÀÛÇÏ¿´´Ù.

(1) Human iPSC¸¦ °£ Àü±¸ ¼¼Æ÷·Î ºÐÈ­ À¯µµ
(2) ºÐÈ­µÈ °£ Àü±¸¼¼Æ÷¸¦ Extracellular matrix¿¡ ¹è¾çÇÏ¿© ´ã°ü³¶ ¼¼Æ÷·Î ºÐÈ­ À¯µµ
(3) ¹ßÇö Marker¸¦ È®ÀÎÇÏ¿© ´ã°ü³¶ ¼¼Æ÷ ºÐÈ­ È®ÀÎ
    (Positive marker: Cytokeratin 7, 19 / Negative marker: ¥á-fetoprotein)
(4) CRISPR/Cas9À¸·Î PRKCSH À¯ÀüÀÚ°¡ ÆíÁýµÈ human iPSC¸¦ Á¦ÀÛÇÏ°í, À̸¦ »ç¿ëÇÏ¿© (1)~(3)°ú °°Àº ¹æ½ÄÀ¸·Î
    ´ã°ü³¶ ¼¼Æ÷·Î ºÐÈ­ À¯µµÇÏ¿© In vitro Áúº´ ¸ðµ¨ Á¦ÀÛ
(5) Á¤»ó ¼¼Æ÷º¸´Ù PRKCSH À¯ÀüÀÚ°¡ ÆíÁýµÈ human iPSC´Â ´ã°ü³¶ ¼¼Æ÷·ÎÀÇ ºÐÈ­°¡ ÃËÁøµÇ´Â °ÍÀ» È®ÀÎ
(6) Human iPSC¿Í À¯ÀüÀÚ ÆíÁý ±â¼úÀ» »ç¿ëÇØ ³­Ä¡¼º ´Ù³¶¼º °£ÁúȯÀÇ in vitro ¸ðµ¨À» ±¸ÃàÇÒ ¼ö ÀÖÀ½À» È®ÀÎ


±×¸²2. Human iPSC À¯·¡ÀÇ °£ Àü±¸¼¼Æ÷¿¡¼­ À¯µµµÈ ´ã°ü³¶ ¼¼Æ÷ÀÇ ±¸Á¶
A: Human iPSC·ÎºÎÅÍ ºÐÈ­µÈ °£ Àü±¸¼¼Æ÷¸¦ extracellular matrix gel¿¡¼­ ¹è¾çÇÏ¿´À¸¸ç, ´ã°ü³¶ ¼¼Æ÷ÀÇ markerÀÎ cytokeratin 19 (CK19) ¾ç¼ºÀÎ ´ã°ü³¶ ±¸Á¶¸¦ È®ÀÎÇÏ¿´´Ù.
B: À¯µµµÈ ´ã°ü³¶ ¼¼Æ÷´Â »óÇÇ Á¶Á÷ÀÇ ±Ø¼º (basal side (¥â-catenin), apical side (PKC¥æ))À» À¯ÁöÇÏ¿´´Ù.

(Kamiya et al., Stem Cell Research (2018) Àοë)
https://www.sciencedirect.com/science/article/pii/1873506118302113

Cellartis¢ç iPS Cell to Hepatocyte Differentiation SystemÀ» ¾î¶»°Ô »ç¿ëÇÏ°Ô µÇ¼Ì³ª¿ä?
¸¹Àº ¿¬±¸ÀÚµéÀÌ ÀÌ¹Ì human iPSC·ÎºÎÅÍ ´Ù¾çÇÑ °£¼¼Æ÷ ºÐÈ­ ¹æ¹ýÀ» º¸°íÇÏ°í ÀÖÀ¸¸ç, ¿ì¸® ¶ÇÇÑ ¿¬±¸ ÁßÀÔ´Ï´Ù.
Feeder cellÀ» »ç¿ëÇÒ °æ¿ì, feeder cell·Î ÀÎÇØ iPSCÀÇ °£¼¼Æ÷ ºÐÈ­ À¯µµ°¡ ºÒ¾ÈÁ¤ÇØ Áú ¼ö Àֱ⠶§¹®¿¡ Feeder-free·Î
iPSCÀÇ ¹è¾çÀÌ °¡´ÉÇÑ Cellartis systemÀ» »ç¿ëÇϱâ·Î °áÁ¤ÇÏ¿´½À´Ï´Ù.
   
½ÇÁ¦·Î »ç¿ëÇغ» ¼Ò°¨Àº ¾î¶»³ª¿ä?
Feeder cellÀ» »ç¿ëÇؼ­ ¹è¾çÇßÀ» ¶§ º¸´Ù CellartisÀÇ iPSC feeder-free culture ¹èÁö (Cellartis¢ç DEF-CS¢â 500 Culture
System (Code Y30010))¿Í °£¼¼Æ÷ ºÐÈ­½Ã½ºÅÛÀ» »ç¿ëÇÏ¿´À» ¶§ ¸Å¿ì °£ÆíÇÏ°Ô Áٱ⼼Æ÷¸¦ ¹è¾çÀ» ÇÒ ¼ö ÀÖ¾ú°í,
human iPSC¸¦ ¸Å¿ì ¾ÈÁ¤ÀûÀ¸·Î °£¼¼Æ÷·Î ºÐÈ­½Ãų ¼ö ÀÖ¾î, ½ÇÇè È¿À²ÀÌ ÇöÀúÇÏ°Ô Áõ°¡Çß½À´Ï´Ù.
   
¾ÆÁ÷ »ç¿ëÇغ¸Áö ¾ÊÀº ºÐµé²² ÇѸ¶µð ºÎŹ µå¸³´Ï´Ù.
Human iPSC¸¦ °£¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤¿¡¼­´Â ÀϹÝÀûÀ¸·Î ¼¼Æ÷ ¹Ðµµ µî¿¡ ÀÇÇØ ºÐÈ­ È¿À²°ú ½ÇÇè °á°ú°¡ Å©°Ô
´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. Cellartis ½Ã½ºÅÛÀº ÀçÇö¼ºÀÌ ³ôÀº ¾ÈÁ¤ÀûÀÎ °á°ú¸¦ Á¦°øÇϱ⠶§¹®¿¡, ½ÇÇè È¿À²À» Áõ°¡½ÃÅ°°íÀÚ
ÇÏ´Â ¿¬±¸ÀÚ¿¡°Ô ÃßõÇÕ´Ï´Ù.
º» Èıâ´Â ÀϹ® ÀÎÅÍºä ³»¿ëÀÇ ¹ø¿ªº»À¸·Î, ¿ø¹®Àº http://www.takara-bio.co.jp ¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.




iPSC Derived Hepatocyte
Human iPSC/ESC·ÎºÎÅÍ °í¼øµµ Hepatocyte·Î ºÐÈ­

Cellartis¢ç iPS Cell to Hepatocyte
Differentiation System (Code Y30055)


  • 25°³ ÀÌ»ó Áٱ⼼Æ÷ÁÖ¿¡¼­ 90% ÀÌ»ó °í¼øµµ °£¼¼Æ÷ ºÐÈ­ È®ÀÎ
  • ´Ü°èº° ºÐÈ­ ÁøÇà, protocol ÃÖÀûÈ­ °úÁ¤ ºÒÇÊ¿ä
  • ³ôÀº ÀçÇö¼ºÀ¸·Î ¾ÈÁ¤ÀûÀÎ ½ÇÇè °á°ú
  • All-in-One Kit·Î ºÐÈ­¿¡ ÇÊ¿äÇÑ ¸ðµç Á¦Ç° Æ÷ÇÔ
Primary Hepatocyte
Human primary hepatocyte ¹è¾çÀ» À§ÇÑ ¼±ÅÃ

Cellartis¢ç Power¢â Primary HEP Medium
(Code Y20020)


  • ´Ù¾çÇÑ Á¦Á¶»çÀÇ Hepatocyte Àå±â ¹è¾ç °¡´É (4ÁÖ)
  • ¾à¹°´ë»ç, ¾à¹°À¯µµ±â´É µî °¢Á¾ metabolism ÃøÁ¤ °¡´É
  • °ÝÀÏ ¹èÁö ±³È¯ (Weekend Free), ¹ø°Å·Î¿î overlay ºÒÇÊ¿ä
  • ´Ù¾çÇÑ Application Àû¿ë : Àå±â °£µ¶¼º ½ÃÇè, HBV, HCV,Intrinsic clearance µî


Ç÷°ü ³»ÇÇ ¼¼Æ÷ (Vascular Endothelial Cells)ÀÇ Áúº´ ¸ðµ¨ °³¹ßÀ» À§ÇÑ Solution
MiraCell¢ç iPS Cell to Endothelial Cell Differentiation Kit (Code Y50300)


  • º¸À¯ ÁßÀÎ human iPSC·ÎºÎÅÍ Ç÷°ü³»ÇǼ¼Æ÷·Î ºÐÈ­ À¯µµ
  • ÃÖÀûÈ­ °úÁ¤ ¾øÀÌ ³ôÀº ºÐÈ­ È¿À² (>80%) È®ÀÎ
  • ºÐÈ­ À¯µµµÈ Ç÷°ü³»ÇǼ¼Æ÷´Â µ¿°á º¸Á¸ ¹× È®´ë ¹è¾ç °¡´É